Dr. Chao Zhou

R&D Director

        Dr. Chao Zhou has over 10 years of experience in cell therapy drug development, overseeing the R&D of CAR-T, CAR-NK, TIL, and MSC products. He is the inventor of 13 cell therapy patents, including 8 invention patents (4 granted) and 5 PCT patents.

        Dr. Zhou established an efficient CRISPR/Cas9-based T cell gene editing platform, achieving over 90% knockout efficiency, and successfully developed PD-1 knockout CAR-T and UCAR-T cells. He participated in the development of the world’s first PD-1 knockout CAR-T targeting MUC1 for the treatment of multiple solid tumors. His work also includes the development of a therapeutic prostate cancer vaccine, achieving recombinant antigen purity exceeding 95%.

        In addition, Dr. Zhou leads the company’s international collaborative research projects with Japan (in the field of immunotherapy) and Harvard University (in the field of genetic diseases).